Clinical Trial

Treatment of Pediatric Bronchiolitis Obliterans by Airway Basal Stem Cells

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
Bronchiolitis obliterans (BO) is a chronic lung disease which was initiated with injury of the bronchiolar epithelium and resulted in nonuniform luminal obliteration or narrowing. Among children, the most common form of BO is post-infectious BO with a lack of treatment guidelines or standard therapy. In this study, an open, single-armed study is performed to preliminarily evaluate the safety and efficacy of airway basal stem cells on treatment of pediatric BO.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-11-16.
Status change: Not Yet Recruiting → Recruiting 2026-01-12
Trial Details
NCT Number NCT07239895
Lead Sponsor Regend Therapeutics
Collaborators: Shanghai Children's Hospital
Conditions Pediatric Bronchiolitis Obliterans
Enrollment 12 participants
Start Date 2025-11-11
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-01-14